Fasudil, the first clinically administered inhibitor of Ras homolog-associated kinase, and is currently used as a therapeutic target for neurodegenerative disorders (Wang et al., 2022), suggesting that drugs targeting Rho/Rho-associated kinases have the potential to alleviate neurodegenerative conditions such as AD. The gene discussed is RHO; the disease is Alzheimer disease.